HIV+Hep in the News

;

Senate confirms vaccine skeptic and AIDS denialist RFK Jr. as health secretary

by | Feb 13, 2025

“We stand ready to work with Secretary Kennedy as he and President Trump seek to improve the health of the American people. Ending infectious and chronic diseases, such as HIV and hepatitis, must be a vital component in the administration’s initiatives,” said Carl Schmid, executive director of the HIV+Hepatitis Policy Institute in a statement. “We were pleased that Kennedy went on record during his confirmation process and stated, ‘I look forward to continuing the good work that President Trump did in his pursuit to eradicate HIV/AIDS.’” (In Trump’s first term, he launched the national initiative “Ending the HIV Epidemic: A Plan for America,” which aimed to lower new HIV rates by 75% by 2025 and by 90% by 2030.)

read more

HIV+Hepatitis Institute Welcomes RFK, Talks Importance of Ending the HIV Epidemic

by | Feb 13, 2025

“To deliver on the promise of eradicating HIV will require a commitment to science, properly funded public health treatment and prevention programs, and policies that support all populations impacted by HIV,” Carl Schmid continues. “It will also require access to affordable and comprehensive health coverage, including private insurance, Medicaid and Medicare.”

read more

Insurer agrees to cover common HIV drugs

by | Feb 10, 2025

“While this action is certainly welcome, the fact remains that Harvard Pilgrim removed lifesaving HIV drugs from its coverage formulary, disrupted the treatment of people living with HIV and violated the nondiscrimination protections [of the Affordable Care Act (ACA), or Obamacare],” said Carl Schmid, executive director of HIV+Hep. “This demonstrates the need for greater oversight of the health insurance industry and enforcement of the safeguards in place to protect patients against the abuse of insurers.”

read more

The hidden cost behind your “$0 copay” drug assistance program

by | Feb 6, 2025

“In one of his executive orders, President Trump is asking agencies to come up with actions they can take that will lower costs for the American people, including health care,” said Carl Schmid, executive director of the HIV+Hepatitis Policy Institute, which advocates for patients with chronic health conditions and was the lead plaintiff in the 2022 court case. “By complying with the court order, it will translate into lower costs for prescription drugs.”

read more

Peter Nelson, Critic Of Coverage Expansions, To Lead CCIIO

by | Feb 6, 2025

Carl Schmid, executive director of the HIV+Hepatitis Policy Foundation, said his group looks forward to working with Nelson, as it did during the first Trump Administration, “to emphasize the needs of patients and the important beneficiary protections that are enshrined in the ACA. If we are going to make America healthy again, these foundational protections cannot be compromised,” he added.

read more

Search

Pin It on Pinterest

Share This